{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:54:52Z","timestamp":1791924892341,"version":"4.3.4"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.atherosclerosis.2022.01.011","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T20:47:25Z","timestamp":1643057245000},"page":"49-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Apolipoproteins and lipoprotein(a) as factors modulating fibrin clot properties in patients with severe aortic stenosis"],"prefix":"10.1016","volume":"344","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9776-440X","authenticated-orcid":false,"given":"Jakub","family":"Siudut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Natorska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Wypasek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Wiewi\u00f3rka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u017cbieta","family":"Ostrowska-Kaim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylwia","family":"Wi\u015bniowska-\u015amia\u0142ek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2973-9952","authenticated-orcid":false,"given":"Krzysztof","family":"Plens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Musialek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2945-3674","authenticated-orcid":false,"given":"Jacek","family":"Legutko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anetta","family":"Undas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib1","doi-asserted-by":"crossref","first-page":"16006","DOI":"10.1038\/nrdp.2016.6","article-title":"Calcific aortic stenosis","volume":"2","author":"Lindman","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib2","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1093\/eurheartj\/ehaa070","article-title":"Plasma lipids and risk of aortic valve stenosis: a Mendelian randomization study","volume":"41","author":"Nazarzadeh","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib3","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1093\/eurheartj\/ehaa172","article-title":"Triglycerides and remnant cholesterol associated with risk of aortic valve stenosis: mendelian randomization in the Copenhagen General Population Study","volume":"41","author":"Kaltoft","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib4","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1161\/01.ATV.0000227513.13697.ac","article-title":"Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more)","volume":"26","author":"O'Brien","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib5","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1161\/01.ATV.16.4.523","article-title":"Apolipoproteins B,(a) , and E accumulate in the morphologically early lesion of \u2018degenerative\u2019 valvular aortic stenosis","volume":"16","author":"O'Brien","year":"1996","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib6","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.atherosclerosis.2018.08.029","article-title":"Inflammatory and metabolic mechanisms underlying the calcific aortic valve disease","volume":"277","author":"Cho","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib42","doi-asserted-by":"crossref","first-page":"100193","DOI":"10.1074\/jbc.RA120.015700","article-title":"ApoC-III is a novel inducer of calcification in human aortic valves","volume":"296","author":"Schlotter","year":"2020","journal-title":"J. Biol. Chem"},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ijcard.2016.09.089","article-title":"Patients with calcific aortic stenosis exhibit systemic molecular evidence of ischemia, enhanced coagulation, oxidative stress and impaired cholesterol transport","volume":"225","author":"Mourino-Alvarez","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib8","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/jth.12229","article-title":"Fibrin(ogen) and thrombotic disease","volume":"11","author":"Ari\u00ebns","year":"2013","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1160\/TH14-10-0861","article-title":"Blood coagulation and fibrinolysis in aortic valve stenosis: links with inflammation and calcification","volume":"114","author":"Natorska","year":"2015","journal-title":"Thromb. Haemostasis"},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1365-2141.2008.07569.x","article-title":"Reduced plasma fibrinolytic capacity as a potential risk factor for a first myocardial infarction in young men","volume":"145","author":"Meltzer","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3109\/09537104.2011.596957","article-title":"Clot lysis time in platelet-rich plasma: method assessment, comparison with assays in platelet-free and platelet-poor plasmas, and response to tranexamic acid","volume":"23","author":"Panes","year":"2012","journal-title":"Platelets"},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1055\/s-0039-1698460","article-title":"Interpretation and validation of maximum absorbance data obtained from turbidimetry analysis of plasma clots","volume":"120","author":"Pieters","year":"2020","journal-title":"Thromb. Haemostasis"},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib13","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.thromres.2015.02.005","article-title":"Shotgun analysis of plasma fibrin clot-bound proteins in patients with acute myocardial infarction","volume":"135","author":"Suski","year":"2015","journal-title":"Thromb. Res."},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib14","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/jth.12122","article-title":"Impaired fibrinolysis is associated with the severity of aortic stenosis in humans","volume":"11","author":"Natorska","year":"2013","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib15","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1160\/TH10-09-0612","article-title":"Fibrin presence within aortic valves in patients with aortic stenosis: association with in vivo thrombin generation and fibrin clot properties, Thromb","volume":"105","author":"Natorska","year":"2011","journal-title":"Haemostasis"},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9062002","article-title":"Impaired fibrinolysis in patients with isolated aortic stenosis is associated with enhanced oxidative stress","volume":"9","author":"Siudut","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib17","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","article-title":"ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"38","author":"Baumgartner","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib18","first-page":"1","article-title":"Obesity: preventing and managing the global epidemic. Report of a WHO consultation","volume":"894","author":"World Health Organization","year":"2000","journal-title":"World Health Organ. Tech. Rep. Ser."},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib19","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1161\/STROKEAHA.108.532812","article-title":"Altered fibrin clot structure\/function in patients with cryptogenic ischemic stroke","volume":"40","author":"Undas","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib20","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/jth.14002","article-title":"An international study on the feasibility of a standardized combined plasma clot turbidity and lysis assay: communication from the SSC of the ISTH","volume":"16","author":"Pieters","year":"2018","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib21","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1053\/gast.2001.25481","article-title":"Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis","volume":"121","author":"Lisman","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib22","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1161\/ATVBAHA.107.153221","article-title":"Heritability of clot formation, morphology, and lysis: the EuroCLOT study","volume":"27","author":"Carter","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2020.10.014","article-title":"Determinants of plasma fibrin clot lysis measured using three different assays in healthy subjects","volume":"197","author":"Siudut","year":"2021","journal-title":"Thromb. Res."},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib24","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0140-6736(08)61076-4","article-title":"Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study","volume":"372","author":"McQueen","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.atherosclerosis.2018.11.006","article-title":"Plasma levels of apolipoproteins C-III, A-IV, and E are independently associated with stable atherosclerotic cardiovascular disease","volume":"281","author":"Dittrich","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib26","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2147\/CLEP.S196266","article-title":"Association of apolipoproteins C-I, C-II, C-III and E with coagulation markers and venous thromboembolism risk","volume":"11","author":"Orsi","year":"2019","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib27","doi-asserted-by":"crossref","DOI":"10.1161\/01.CIR.0000033221.73082.06","article-title":"Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease","volume":"106","author":"Mills","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib28","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/eurheartj\/ehy013","article-title":"Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy","volume":"39","author":"Sumaya","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib29","first-page":"1","article-title":"Fibrin clot properties in coronary artery disease: new determinants and prognostic markers","author":"Larsen","year":"2021","journal-title":"Pol. Arch. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041966","article-title":"Identification of fibrin clot-bound plasma proteins","volume":"7","author":"Talens","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib31","doi-asserted-by":"crossref","first-page":"103946","DOI":"10.1016\/j.jprot.2020.103946","article-title":"Plasma fibrin clot proteomics in patients with acute pulmonary embolism : association with clot properties","volume":"229","author":"Bryk","year":"2020","journal-title":"J. Proteonomics"},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib32","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/MBC.0b013e32835a083c","article-title":"High-density cholesterol and apolipoprotein AI as modifiers of plasma fibrin clot properties in apparently healthy individuals","volume":"24","author":"Zabczyk","year":"2013","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib33","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1194\/jlr.R060582","article-title":"Thematic review series: lipoprotein (a): coming of age at last: lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?","volume":"57","author":"Boffa","year":"2016","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2020.03.003","article-title":"The dedicated \u201cLp(a) clinic\u201d: a concept whose time has arrived?","volume":"300","author":"Tsimikas","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib35","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/j.1538-7836.2006.01903.x","article-title":"Lipoprotein(a) as a modifier of fibrin clot permeability and susceptibility to lysis","volume":"4","author":"Undas","year":"2006","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib36","doi-asserted-by":"crossref","DOI":"10.1111\/j.1538-7836.2007.02637.x","article-title":"Altered fibrin clot structure in patients with advanced coronary artery disease: a role of C-reactive protein, lipoprotein(a) and homocysteine","volume":"5","author":"Undas","year":"2007","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib37","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1016\/j.thromres.2012.06.005","article-title":"Altered fibrin clot properties are associated with residual vein obstruction: effects of lipoprotein(a) and apolipoprotein(a) isoform","volume":"130","author":"Undas","year":"2012","journal-title":"Thromb. Res."},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib38","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.3390\/jcm9082476","article-title":"Chronic kidney disease and its impact on a prothrombotic state in patients with atrial fibrillation","volume":"9","author":"Matusik","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib39","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/MBC.0000000000000462","article-title":"Increased fibrin formation and impaired fibrinolytic capacity in severe chronic kidney disease","volume":"27","author":"M\u00f6rtberg","year":"2016","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib40","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1160\/th14-05-0468","article-title":"The influence of type 2 diabetes on fibrin clot properties in patients with coronary artery disease, Thromb","volume":"112","author":"Neergaard-Petersen","year":"2014","journal-title":"Haemostasis"},{"key":"10.1016\/j.atherosclerosis.2022.01.011_bib41","doi-asserted-by":"crossref","first-page":"103487","DOI":"10.1016\/j.jprot.2019.103487","article-title":"Plasma fibrin clot proteomics in healthy subjects: relation to clot permeability and lysis time","volume":"208","author":"Z\u0105bczyk","year":"2019","journal-title":"J. Proteonomics"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915022000259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915022000259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:48:20Z","timestamp":1758156500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915022000259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":42,"alternative-id":["S0021915022000259"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.01.011","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apolipoproteins and lipoprotein(a) as factors modulating fibrin clot properties in patients with severe aortic stenosis","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}